top of page

Partners

The UltiMalVax consortium has an incredibly wide expertise and experience with immunogen design, pre-clinical immunogenicity and efficacy models of malaria, immunoassays of functional antibodies and other potential immune correlates.

Novel technologies from biotech companies prepared to provide access to these for malaria (e.g. thermostable mRNA), a leading PDP with a long malaria vaccine track record as coordinator, access to a leading licensed saponin adjuvant and many promising new adjuvant formulations, GMP manufacturing capability, and deep expertise in vaccine clinical development and product licensure.

bottom of page